FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfilePatrys Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
PAB.AX
Patrys Limited Stock AnalysisComprehensive stock analysis for Patrys Limited (PAB.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisPAB.AX
PAB.AX
Patrys Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
PAB.AX
  1. Home
  2. Stocks
  3. Patrys Limited

Patrys Limited

🇦🇺PAB.AX•ASX

Patrys Limited

🇦🇺PAB.AX•ASX

Your view on PAB.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Patrys Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Samantha South
Headquarters
168 Stirling Highway, Nedlands, WA, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Samantha South
Headquarters
168 Stirling Highway, Nedlands, WA, AU
Description

Based in Melbourne, Australia, Patrys Limited and its subsidiaries specialize in developing and commercializing advanced antibody technologies for cancer treatment. Their leading therapeutic, Deoxymab 3E10, is a distinctive DNA damage-repair antibody capable of penetrating cell nuclei.

The company's pipeline also includes PAT-DX1, an antibody fragment specifically designed to target both primary and secondary brain cancers.

Furthermore, Patrys is progressing PAT-DX3, a full-sized antibody that shares PAT-DX1's DNA-binding and DNA damage repair blocking properties, currently being evaluated for its tissue distribution and pharmacokinetic profile.

Another promising development is PAT-DX1-NP, a product leveraging the targeted delivery of therapeutic payload-carrying nanoparticles directly into cancer cells. Patrys Limited was established in 2006.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Patrys Limited. Starting points for Patrys Limited: EPS -AUD 0.0083, beta 1.25 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Patrys Limited. Patrys Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Patrys Limited. Trailing twelve-month EPS for Patrys Limited stands at -AUD 0.0083. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 20, 2026 · AUD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Earnings Estimate

EPSCurrent QtrDec 2026
Avg. estimateAUD 0.00
Low estimateAUD 0.00
High estimateAUD 0.00
No. of analysts0
Year-ago EPS—
Growth—

Revenue Estimate

RevenueCurrent QtrDec 2026
Avg. estimateAUD 5880.00
Low estimateAUD 5880.00
High estimateAUD 5880.00
No. of analysts1
Year-ago revenue—
Growth—

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 20, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Patrys Limited. Patrys Limited has reported as a listed company since 2007. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold PAB.AX18 companies
Compare PAB.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
AVE.AXAvecho Biotechnology LimitedHealthcareBiotechnology—
BTC.AXBTC Health LimitedHealthcareBiotechnology—
CHM.AXChimeric Therapeutics LimitedHealthcareBiotechnology—
IMC.AXImmuron LimitedHealthcareBiotechnology—
IME.AXImExHS LimitedHealthcareMedical - Diagnostics & Research—
NC6.AXNanollose LimitedHealthcareBiotechnology—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PANCPanacos Pharmaceuticals, Inc.HealthcareOTC$5,367
PAR.AXParadigm Biopharmaceuticals LimitedHealthcareASX—
PARDPoniard Pharmaceuticals, Inc.HealthcareOTC$150
PASGPassage Bio, Inc.HealthcareNASDAQ$12.9M
PBIGFParadigm Biopharmaceuticals LimitedHealthcareOTC$87.9M
PBLAPanbela Therapeutics, Inc.HealthcareOTC$53,889
PBLSParabilis Medicines, Inc.HealthcareNASDAQ$3.5B
PBMPsyence Biomedical Ltd.HealthcareNASDAQ$47,738
PBMWWPsyence Biomedical Ltd. WarrantHealthcareNASDAQ$869
PBYIPuma Biotechnology, Inc.HealthcareNASDAQ$373.3M
PCSAProcessa Pharmaceuticals, Inc.HealthcareNASDAQ$4.8M
PCVXVaxcyte, Inc.HealthcareNASDAQ$9.3B
Open Comparable Analysis
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Patrys Limited. Coverage tracks Patrys Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Patrys Limited.

PAB.AX AnalysisGood
Past
5
Growth
5
Health
5
Profit
1
Value
1

News

Latest Market News